All In Biotech

Investigational drug · Phase 2

Zugocabtagene geleucel

Also called: CTX112

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy.

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

2

Any phase or sponsor naming "Zugocabtagene geleucel"

First trial start

2023

Mar 10, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Zugocabtagene geleucel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • B-cell Lymphoma
  • Non-Hodgkin Lymphoma
  • B-cell Malignancy
  • Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • Large B-cell Lymphoma
  • Progressive Multiple Sclerosis (PMS)
  • Neuromyelitis Optica

Approved drugs for the same conditions: Chronic lymphocytic leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Multiple sclerosis · Hematology and blood cancers · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "Zugocabtagene geleucel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for B-cell Lymphoma

  • NX-5948bexobrutidegPhase 33 trials

    Nurix Therapeutics, Inc. · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

  • TQB3702Phase 22 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · B-cell Lymphoma, Systemic Lupus Erythematosus

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.